Operational aspects of terminating the doxazosin arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Controlled Clinical Trials

Volumn 22, Issue 1, 2001, Pages 29-41

  Pressel, Sara L ^a,g   Davis, Barry R ^a   Wright Jr , Jackson T ^b   Geraci, Therese S ^c   Kingry, Connie ^d   Ford, Charles E ^a   Piller, Linda B ^a   Bettencourt, Judy ^a   Kimmel, Barbara ^a   Lusk, Christine ^a   Parks, Heather ^a   Simpson, Lara M ^a   Nwachuku, Chuke ^e   Furberg, Curt D ^f  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f WAKE FOREST UNIVERSITY   (United States)

^g ALLHAT Clinical Trials Center   (United States)

Author keywords

Clinical trials; Closeout; Early termination; Large simple trial

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; CALCIUM ANTAGONIST; CHLORTALIDONE; CHOLESTEROL; CLONIDINE; DIURETIC AGENT; DOXAZOSIN; LISINOPRIL; LOW DENSITY LIPOPROTEIN; PRAVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MONITORING; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIHYPERTENSIVE AGENTS; CAUSE OF DEATH; CORONARY DISEASE; DATABASES, FACTUAL; DOUBLE-BLIND METHOD; DOXAZOSIN; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRAVASTATIN; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 0035150931     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(00)00109-4     Document Type: Article

References (18)

1. Monitoring treatment differences in long-term clinical trials
2. A multiple testing procedure for clinical trials
3. Group sequential methods in the design and analysis of clinical trials
4. Discrete sequential boundaries for clinical trials
5. An aid to data monitoring in long-term clinical trials
6. Statistical aspects of early termination in the Beta-Blocker heart attack trial
7. Stochastically curtailed tests in long term clinical trials
8. The B-value: A tool for monitoring data
9. Effects of assumption violations on type I error rate in group sequential monitoring
10. Terminating a long-term clinical trial
11. Closing down the study
12. Changing the protocol: A case report from the Macular Photocoagulation Study
13. Termination of clinical trials: The Beta-Blocker Heart Attack Trial and the Hypertension Detection and Follow-up Program experience
14. Operational aspects of terminating randomization in the multicenter trial of cryotherapy for retinopathy of prematurity
15. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
16. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone - The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
17. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure